Lantheus Holdings Inc at Goldman Sachs Healthcare Conference Transcript
Okay. We'll continue with the next session. I'm Paul Choi, and I cover SMID-cap biotech sector here at the firm. It's my pleasure to have Lantheus here for our next panel. To my left is John Wiggins, who is VP, I think, formerly of Isotope Strategy, but I think he's in a slightly new role here, if I recall.
What we'll do is let John kick it off maybe with some high-level comments, and then we'll get into Q&A. If there are any, please feel free to raise your hand, and we'll try and get a mic to you during the session. So maybe to kick it off, John, if we can talk about what are Lantheus' strategic priorities for the remainder of 2026 and as the company goes into 2027?
Yeah, absolutely, Paul. So Lantheus is a leading radiopharmaceutical focused company. We are particularly focused on diagnostic radiopharmaceutical agents. And really, when we think about what we're doing for the rest of this year and then going into next year as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
